Fall 2026

Construction Accounting Intern

Construction Accounting

Posted on 7/30/2026

BioMed Realty

BioMed Realty

201-500 employees

Life science lab and office REIT

Compensation Overview

$25 - $30/hr

San Diego, CA, USA

In Person

Onsite in San Diego, California; in-office schedule Monday-Thursday within 8AM-5PM.

Bachelor's

Category
Accounting (1)

Get referred to BioMed Realty

See people who can refer or advise you

Requirements
  • Pursuing a degree with a major or minor in Accounting
  • Interested in real estate, construction, or project-based accounting
  • Detail-oriented with strong analytical and organizational skills
  • Able to manage multiple priorities and meet deadlines
  • Available to work up to 20 hours per week during the academic year
Responsibilities
  • Assist in preparing and posting journal entries related to construction accounting activities
  • Support the review and processing of construction invoices, budgets, and contracts
  • Perform monthly balance sheet reconciliations and account analysis
  • Contribute to month-end close activities, including reporting and documentation
  • Collaborate with accounting team members across experience levels
  • Research and evaluate emerging A.I. tools for accounting related functions. Collaborate with cross‑functional team members to identify opportunities for A.I. usage and adoption.
Desired Qualifications
  • Research and evaluate emerging A.I. tools for accounting related functions
  • Collaborate with cross-functional team members to identify opportunities for A.I. usage and adoption

BioMed Realty is a real estate investment trust that provides laboratory and office space to life science companies in the United States and the United Kingdom. It earns income mainly from long-term leases with biotechnology and pharmaceutical tenants and also develops and redevelops properties to meet evolving tenant needs. It differentiates itself by focusing on purpose-built lab spaces and by combining leasing, asset management, and development on one platform. Its goal is to support life-science research and commercialization while delivering steady returns for investors.

Company Size

201-500

Company Stage

N/A

Total Funding

$598.6M

Headquarters

San Diego, California

Founded

2004

Get referred to BioMed Realty

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • On January 12, 2026, TransMedics signed a 498,000-square-foot lease at Assembly Innovation Park.
  • On February 24, 2026, BioMed fully leased Babraham's newest building with TRIMTECH and Tagomics.
  • Leadership promotions on January 27, 2026 strengthened accounting, asset management, and West Coast leasing.

What critics are saying

  • On July 27, 2026, BioMed surrendered Boston's 1000 Washington and 321 Harrison to lenders.
  • A 2025 judge denied BioMed's intervention in the $16 million Lyndra lease fight.
  • Weak life-science demand can strand newly built labs, forcing more lender takeovers by 2027.

What makes BioMed Realty unique

  • BioMed Realty is the largest private life-science landlord across U.S. and U.K. hubs.
  • Its 17.3 million-square-foot portfolio offers purpose-built labs, not generic office boxes.
  • Blackstone ownership funds development, redeployment, and patient capital through leasing cycles.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Time Off

Paid Family Leave Benefits

401(k) Retirement Plan

Tuition Reimbursement

Flexible Spending Accounts

Commuter Benefits

Lifestyle Spending Account

Pet Insurance

ID Theft Insurance

Legal Insurance

Employee Assistance Program

100% Employer-Paid Life & AD&D Insurance

Short and Long Term Disability

Company News

AnaptysBio
Apr 13th, 2026
AnaptysBio Secures $40 Million Series D Financing | AnaptysBio, Inc.

Enables Advancement of First-In-Class Anti-Inflammatory Antibody Programs Through Key Clinical Studies   SAN DIEGO, California — AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology, today announced the completion of an

INACTIVE